Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-10-29
1999-10-12
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142388, 514241, 514248, 514253, 514255, 514256, 514365, 514369, 514374, 514376, 514396, 514397, 514529, 514546, 514547, 544106, 544215, 544216, 544264, 544265, 544298, 544335, 544336, 544350, 544355, 548204, 548236, 5483111, 5483351, 5483435, 560 42, 562567, 562577, 568307, A61K 31495, C07D24138
Patent
active
059655585
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to novel protein tyrosine phosphatase modulating compounds, to methods for their preparation, to compositions comprising the compounds, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phosphotyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryoic cells, whole animals and human beings.
BACKGROUND OF THE INVENTION
Reversible phosphorylation of proteins is a prevalent biological mechanism for modulation of enzymatic activity in living organisms. Tonks et al., J. Biol. Chem., 263(14):6722-30 (1988). Such reversible phosphorylation requires both a protein kinase (PK), to phosphorylate a protein at a particular amino acid residue, and a protein phosphatase (PP), to remove the phosphate moieties. See generally, Hunter, Cell, 80:225-236 (1995). Recently, it has been estimated that humans have as many as 2000 conventional PK genes, and as many as 1000 PP genes. Id.
One major class of PK's/PP's--the protein serine/threonine kinases and protein serine/threonine phosphatases--have been shown to play critical roles in the regulation of metabolism. See generally, Cohen, Trends Biochem. Sci., 17:408-413 (1992); Shenolikar, Ann. Rev. Cell Biol., 10:55-86 (1994); Bollen et al., Crit. Rev. Biochem. Mol. Biol., 27:227-81 (1992). As their name suggests, these enzymes phosphorylate and dephoshphorylate serine or threonine residues of substrate proteins. Inhibitors of protein serine/threonine phosphatases and kinases have been described. See, e.g., MacKintosh and MacKintosh, TIBS, 19:444-448 (1994).
The protein tyrosine kinases/phosphatases comprise a second, distinct family of PK/PP enzymes of significant interest, and have been implicated in the control of normal and neoplastic cell growth and proliferation. See Fisher et al., Science, 253:401-406 (1991). Protein tyrosine kinase (PTK) genes are ancient in evolutionary origin and share a high degree of inter-species conservation. See generally Hunter and Cooper, Ann. Rev. Biochem., 54:897-930 (1985). PTK enzymes exhibit high specificity for tyrosine, and ordinarily do not phosphorylate serine, threonine, or hydroxyproline.
More than 75 members of the PTPase family have been identified in eukaryotes, prokaryotes, and even viruses. Tonks and Neel, Cell 87:365-368. Protein tyrosine phosphatases (PTPases) were originally identified and purified from cell and tissue lysates using a variety of artificial substrates, and therefore their natural functions and substrates were not obvious. However, their roles in cellular processes, including cell-cell contact and cell adhesion, and growth factor and antigen signaling events, have begun to be elucidated.
PTPases are generally grouped into two categories: those which have both an extracellular domain and an intracellular catalytic domain, the receptor PTPases (R-PTPases); and those which are entirely intracellular. For R-PTPases much effort has been directed at determining the function of the extracellular domain. Most of the R-PTPases contain extracellular domains which are structurally similar to domains found in known adhesion molecules; these domains include fibronectin type III repeats, immunoglobulin domains, and cadherin extracellular repeats. See generally Brady-Kalnay and Tonks, Curr. Opin. Cell. Biol. 7:650-657 (1995); Streuli, Curr. Opin. Cell. Biol. 8:182-188 (1996). This homology with proteins known to be involved in adhesion suggested a role for these R-PTPases in regulating or mediating adhesion events. For several of the R-PTPases, this has now been demonstrated.
Cells form specialized structures at the sites of cell-cell contact (adherens junctions) and cell-extracellular matrix contact (focal adhesion). Multiple signal transduction molecules are recruited to these sites, including severa
REFERENCES:
patent: 5206392 (1993-04-01), Dean
Cao, X. et al., Bioorganic & Medicinal Chemistry Letters, vol. 5, No. 24, pp. 2953-2958, (1995).
Arena, G. et al., J. Chem. Soc. Perkin 2, (1993), (10) pp. 1941-1945.
Crump, R.A.N.C. et al, J. Chem. Soc. Perkin 1, (1992) (24) pp. 3277-3294.
Levitzki et al., "Tyrosine Kinase Inhibition: An Approach to Drug Development," Science, vol. 267, pp. 1782-1788, Mar. 24, 1995.
Bakir Farid
Cao Xiaodong
Mjalli Adnan
Sarshar Sepehr
Chow Frank S.
Ontogen Corporation
Oswecki Jane C.
Richter Johann
LandOfFree
Modulators of proteins with phosphotyrosine recognition units does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of proteins with phosphotyrosine recognition units, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of proteins with phosphotyrosine recognition units will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-652682